Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The breakthrough drug designation, patients driving progress

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.07.18
Views: 454

Dr Ellen V. Sigal - Friends of Cancer Research, Washington D.C., USA

Dr Sigal speaks with ecancer at the 2018 WIN symposium about her experience in patient care, and implementing science in policy.

She starts by discussing the Breakthrough Drug Designation which accelerates the approval breakthrough drugs based on preliminary evidence.

Dr Sigal also discusses the Lung-MAP trial and the integral involvement of patients in all of the work she does.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation